Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.81 |
| ▸ | GNA15 | P30679 | 1/20 | 0.79 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.79 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.79 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123745 | 0.92 | FFAR1 (0.79) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL24723627 | 0.90 | FFAR1 (0.65) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1633142 | 0.90 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17911219 | 0.90 | FFAR1 (0.65) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16532871 | 0.90 | FFAR1 (0.65) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16515346 | 0.90 | FFAR1 (0.65) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL206660 | 0.90 | FFAR1 (0.83) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16123793 | 0.89 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| Fasiglifam SCHEMBL16448782 | 0.88 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| Fasiglifam SCHEMBL16448793 | 0.88 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019134984-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2019-07-11 | — | — | WO | disclosed |